Open Drug Discovery Center for Alzheimer's Disease

阿尔茨海默病开放药物发现中心

• 批准号: 10475134
• 负责人: ALLAN I LEVEY
• 金额: $ 84.88万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10475134
• 关键词: Address; Alzheimer' s Disease; Antibodies; Attention; Automobile Driving; Binding; Bioinformatics; Biological; Biological Assay; Biology; Biomedical Research; CD44 gene; Cell Line; Cells; Chemicals; Collaborations; Communities; Complex; Consultations; Crystallization; Data; Development; Diamond; Disease; Drug Targeting; Ensure; Enzymes; Foundations; Funding; Generations; Genes; Human; Human Biology; Individual; Integral Membrane Protein; Intervention; Knock-out; Knowledge; Lead; Ligand Binding; Ligands; Link; Physiological; Pilot Projects; Program Development; Proteins; RIPK2 gene; Reagent; Reproducibility; Research; Research Personnel; Resolution; Resources; Role; Route; Scientist; Site; Structure; Synchrotrons; System; Testing; Time; Validation; Work; antibody inhibitor; assay development; base; drug development; drug discovery; experimental study; knockout gene; moesin; peer; protein complex; protein function; reconstitution; screening; small molecule; structural biology; therapeutic evaluation; tool

The Open Drug Discovery Center for AD (Open-AD) Structural Biology core aims to provide Target Enabling Packages (TEPs): a combination of experimental tools and knowledge that will allow researchers to investigate the biology of potential drug targets and to test therapeutic hypotheses. The TEPs will consist of: gene knockout reagents and cell lines; purified target proteins for functional studies and for the development of antibodies and inhibitors; and structures of proteins and protein:ligand complexes, to understand protein functions and support drug development. Target selection and the definition of the required experimental tools will be determined in consultation with the Bioinformatics and the Admin and Data Cores, which will bring in community expertise. The Structural Biology core will have a central role within the Open-AD project, providing purified proteins for assay development and screening by the Assay core and structural data to guide chemical development by the MedChem core. By releasing all reagents and data, we will enable and promote deeper and wider study by the biomedical research community. The Structural Biology core team is already engaged in active collaboration with the Mangravite and Levey groups, generating TEPs for targets discovered in the AMP-AD consortium; some of these TEPs will form the basis of the first chemical development programs within the new proposed Open-AD project.

AD结构生物学开放药物发现中心（Open Drug Discovery Center for AD，Open-AD）的核心目标是提供 目标使能包（TEPs）：实验工具和知识的组合， 使研究人员能够研究潜在药物靶点的生物学， 假设TEP将包括：基因敲除试剂和细胞系;纯化的靶细胞; 用于功能研究以及用于开发抗体和抑制剂的蛋白质;以及 蛋白质和蛋白质的结构：配体复合物，了解蛋白质的功能和支持 药物开发目标选择和所需实验工具的定义将在 与生物信息学和管理和数据核心协商确定， 引入社区专业知识。结构生物学核心将在 Open-AD项目，提供纯化的蛋白质用于检测开发和筛选， 分析核心和结构数据，以指导MedChem核心的化学开发。通过 释放所有试剂和数据，我们将使和促进更深入和更广泛的研究， 生物医学研究社区。结构生物学核心团队已经在积极参与 与Mangravite和Levey小组合作，为发现的目标生成TEP， AMP-AD联合体;其中一些TEPs将成为第一种化学品的基础 在新提出的Open-AD项目中的开发计划。